Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D018579:Patient Selection; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D012107:Research Design; D013601:T-Lymphocytes; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016853:Muromonab-CD3; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab